Search

Your search keyword '"Taveggia, Paola"' showing total 20 results
Start Over Author "Taveggia, Paola"
20 results on '"Taveggia, Paola"'

1. Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA)

Author

Passiglia, Francesco, Listì, Angela, Bironzo, Paolo, Merlini, Alessandra, Benso, Federica, Napoli, Francesca, Barbu, Francesca Alice, Zambelli, Vanessa, Tabbò, Fabrizio, Reale, Maria Lucia, Sini, Claudio, Roca, Elisa, Taveggia, Paola Adriana, Simionato, Francesca, Buffoni, Lucio, Mazilu, Laura, Barbieri, Vito, Pignataro, Daniele, Araujo, Antonio, Paz-Ares, Luis, Felip, Enriqueta, Secen, Nevena, Comanescu, Alina, Ramizi, Kleida Mati, Bettini, Anna Cecilia, Scotti, Vieri, Linardou, Helena, Mohorcic, Katja, Meoni, Giulia, Giannarelli, Diana, Volante, Marco, Malapelle, Umberto, Vallone, Stefania, Scagliotti, Giorgio, Righi, Luisella, and Novello, Silvia

Published
2024
Full Text
View/download PDF

3. Actionable Non-Small Cell Lung Cancer Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients with Advanced Lung Cancer (Epropa)

Author

Passiglia, Francesco, primary, Listì, Angela, additional, Bironzo, Paolo, additional, Merlini, Alessandra, additional, Benso, Federica, additional, Napoli, Francesca, additional, Barbu, Francesca Alice, additional, Zambelli, Vanessa, additional, Tabbò, Fabrizio, additional, Reale, Maria Lucia, additional, Sini, Claudio, additional, Roca, Elisa, additional, Taveggia, Paola Adriana, additional, Simionato, Francesca, additional, Buffoni, Lucio, additional, Mazilu, Laura, additional, Barbieri, Vito, additional, Pignataro, Daniele, additional, Araújo, Antonio, additional, Paz Ares, Luis, additional, Felip, Enriqueta, additional, Secen, Nevena, additional, Comanescu, Alina, additional, Madi, Kleida, additional, Bettini, Anna Cecilia, additional, Scotti, Vieri, additional, Linardou, Helena, additional, Mohorcic, Katja, additional, Meoni, Giulia, additional, Volante, Marco, additional, Malapelle, Umberto, additional, Vallone, Stefania, additional, Scagliotti, Giorgio Vittorio, additional, Righi, Luisella, additional, and Novello, Silvia, additional

Published
2024
Full Text
View/download PDF

4. Antibody Response to COVID-19 mRNA Vaccines in Oncologic and Hematologic Patients Undergoing Chemotherapy

Author

Mencoboni, Manlio, primary, Fontana, Vincenzo, additional, Damiani, Azzurra, additional, Spitaleri, Antonino, additional, Raso, Alessandro, additional, Bottaro, Luigi Carlo, additional, Rossi, Giovanni, additional, Canobbio, Luciano, additional, La Camera, Antonella, additional, Filiberti, Rosa Angela, additional, Taveggia, Paola, additional, and Cavo, Alessia, additional

Published
2022
Full Text
View/download PDF

6. Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA)

Author

Passiglia, Francesco, Listì, Angela, Bironzo, Paolo, Merlini, Alessandra, Benso, Federica, Napoli, Francesca, Barbu, Francesca Alice, Zambelli, Vanessa, Tabbò, Fabrizio, Reale, Maria Lucia, Sini, Claudio, Roca, Elisa, Taveggia, Paola Adriana, Simionato, Francesca, Buffoni, Lucio, Mazilu, Laura, Barbieri, Vito, Pignataro, Daniele, Araujo, Antonio, Paz-Ares, Luis, Felip, Enriqueta, Secen, Nevena, Comanescu, Alina, Ramizi, Kleida Mati, Bettini, Anna Cecilia, Scotti, Vieri, Linardou, Helena, Mohorcic, Katja, Meoni, Giulia, Giannarelli, Diana, Volante, Marco, Malapelle, Umberto, Vallone, Stefania, Scagliotti, Giorgio, Righi, Luisella, and Novello, Silvia

Abstract

The advocacy Women Against Lung Cancer in Europe (WALCE) promoted the European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA) and provided a free-of-charge molecular profiling platform for NSCLC sample characterization with the aim of increasing the detection of targetable drivers and improving patients’ access to clinical trials in Europe.

Published
2025
Full Text
View/download PDF

9. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists

Author

Ottaviano, Margaret, primary, Curvietto, Marcello, additional, Rescigno, Pasquale, additional, Tortora, Marianna, additional, Palmieri, Giovannella, additional, Giannarelli, Diana, additional, Aieta, Michele, additional, Assalone, Pasquale, additional, Attademo, Laura, additional, Avallone, Antonio, additional, Bloise, Francesco, additional, Bosso, Davide, additional, Borzillo, Valentina, additional, Buono, Giuseppe, additional, Calderoni, Giuseppe, additional, Caputo, Francesca, additional, Cartenì, Giacomo, additional, Cavallero, Diletta, additional, Cavo, Alessia, additional, Ciardiello, Fortunato, additional, Conca, Raffaele, additional, Conteduca, Vincenza, additional, De Falco, Stefano, additional, De Felice, Marco, additional, De Laurentiis, Michelino, additional, De Placido, Pietro, additional, De Placido, Sabino, additional, De Santo, Irene, additional, De Stefano, Alfonso, additional, Della Corte, Carminia Maria, additional, Di Franco, Rossella, additional, Di Lauro, Vincenzo, additional, Fabbrocini, Antonietta, additional, Federico, Piera, additional, Festino, Lucia, additional, Giordano, Pasqualina, additional, Giuliano, Mario, additional, Gridelli, Cesare, additional, Grimaldi, Antonio Maria, additional, Lia, Michela, additional, Marretta, Antonella Lucia, additional, Massa, Valentina, additional, Mennitto, Alessia, additional, Merler, Sara, additional, Merz, Valeria, additional, Messina, Carlo, additional, Messina, Marco, additional, Milano, Monica, additional, Minisini, Alessandro Marco, additional, Montesarchio, Vincenzo, additional, Morabito, Alessandro, additional, Morgillo, Floriana, additional, Mucci, Brigitta, additional, Nappi, Lucia, additional, Napolitano, Fabiana, additional, Paciolla, Immacolata, additional, Pagliuca, Martina, additional, Palmieri, Giuseppe, additional, Parola, Sara, additional, Pepe, Stefano, additional, Petrillo, Angelica, additional, Piantedosi, Francovito, additional, Piccin, Luisa, additional, Picozzi, Fernanda, additional, Pietroluongo, Erica, additional, Pignata, Sandro, additional, Prati, Veronica, additional, Riccio, Vittorio, additional, Rosanova, Mario, additional, Rossi, Alice, additional, Russo, Anna, additional, Salati, Massimiliano, additional, Santabarbara, Giuseppe, additional, Sbrana, Andrea, additional, Simeone, Ester, additional, Silvestri, Antonia, additional, Spada, Massimiliano, additional, Tarantino, Paolo, additional, Taveggia, Paola, additional, Tomei, Federica, additional, Vincenzo, Tortora, additional, Trapani, Dario, additional, Trojanello, Claudia, additional, Vanella, Vito, additional, Vari, Sabrina, additional, Ventriglia, Jole, additional, Vitale, Maria Grazia, additional, Vitiello, Fabiana, additional, Vivaldi, Caterina, additional, von Arx, Claudia, additional, Zacchi, Francesca, additional, Zampiva, Ilaria, additional, Zivi, Andrea, additional, Daniele, Bruno, additional, and Ascierto, Paolo Antonio, additional

Published
2020
Full Text
View/download PDF

11. Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma

Author

Mencoboni, Manlio, primary, Filiberti, Rosa A., additional, Taveggia, Paola, additional, Grosso, Federica, additional, Pasello, Giulia, additional, Del Corso, Lisette, additional, Muzio, Alberto, additional, Polo, Valentina, additional, Zucali, Paolo, additional, Ceresoli, Giovanni L., additional, Soto Parra, Hector J., additional, Auriati, Laura, additional, and Simonassi, Claudio, additional

Published
2017
Full Text
View/download PDF

12. Clinicopathological features of patients with malignant mesothelioma in a multicenter, retrospective study.

Author

Mencoboni, Manlio, primary, Filiberti, Rosa, additional, DelCorso, Lisette, additional, Bruzzone, Andrea, additional, Grosso, Federica, additional, Pasello, Giulia, additional, Favaretto, Adolfo G., additional, Soto Parra, Hector J., additional, Taveggia, Paola, additional, Perrino, Matteo, additional, Zucali, Paolo Andrea, additional, and Ceresoli, Giovanni Luca, additional

Published
2015
Full Text
View/download PDF

15. Predicting the Risk of Pancreatic Cancer: On CDKN2A Mutations in the Melanoma-Pancreatic Cancer Syndrome in Italy

Author

Ghiorzo, Paola, primary, Gargiulo, Sara, additional, Nasti, Sabina, additional, Pastorino, Lorenza, additional, Battistuzzi, Linda, additional, Bruno, William, additional, Bonelli, Luigina, additional, Taveggia, Paola, additional, Pugliese, Vittorio, additional, Borgonovo, Giacomo, additional, Mastracci, Luca, additional, Fornarini, Giuseppe, additional, Romagnoli, Paola, additional, Iiritano, Elena, additional, Savarino, Vincenzo, additional, and Bianchi-Scarrà, Giovanna, additional

Published
2007
Full Text
View/download PDF

16. Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: A phase II trial from an Italian cooperative group

Author

Benasso, Marco, primary, Ponzanelli, Anna, additional, Merlano, Marco, additional, Numico, Gianmuro, additional, Ricci, Isabella, additional, Vigo, Viviana, additional, Grossi, Francesco, additional, Amadori, Dino, additional, Cavallo, Giovanna, additional, Capaccetti, Barbara, additional, Taveggia, Paola, additional, Boni, Luca, additional, and Rosso, Riccardo, additional

Published
2006
Full Text
View/download PDF

18. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists

Author

Sara Parola, Diletta Cavallero, Pietro De Placido, Rossella Di Franco, Francesca Zacchi, Giacomo Cartenì, Sabino De Placido, Claudia von Arx, Alice Rossi, Fernanda Picozzi, Pasquale Rescigno, Laura Attademo, Giovannella Palmieri, Carminia Maria Della Corte, Fabiana Vitiello, Anna Russo, Lucia Nappi, Michele Aieta, Alessia Mennitto, Fabiana Napolitano, Marco Messina, Giuseppe Buono, Valeria Merz, Marco De Felice, Stefano De Falco, Immacolata Paciolla, Irene De Santo, Dario Trapani, Antonio M. Grimaldi, Paolo Tarantino, Alessandro Morabito, Tortora Vincenzo, Stefano Pepe, Giuseppe Palmieri, Antonietta Fabbrocini, Diana Giannarelli, Alfonso De Stefano, Sabrina Vari, Cesare Gridelli, Vittorio Riccio, Angelica Petrillo, Martina Pagliuca, Giuseppe Calderoni, Margaret Ottaviano, Vincenza Conteduca, Michela Lia, Giuseppe Santabarbara, Ester Simeone, Valentina Borzillo, Francesca Caputo, Mario Rosanova, Marcello Curvietto, Pasquale Assalone, Brigitta Mucci, Raffaele Conca, Vito Vanella, Francovito Piantedosi, Vincenzo Montesarchio, Erica Pietroluongo, Lucia Festino, Federica Tomei, Vincenzo Di Lauro, Bruno Daniele, Caterina Vivaldi, Andrea Zivi, Veronica Prati, Pasqualina Giordano, Luisa Piccin, Francesco Bloise, Massimiliano Spada, Jole Ventriglia, Davide Bosso, Alessandro Marco Minisini, Massimiliano Salati, Monica Milano, Carlo Messina, Valentina Massa, Mario Giuliano, Claudia Trojanello, Antonella Lucia Marretta, Fortunato Ciardiello, Antonio Avallone, Marianna Tortora, Ilaria Zampiva, Alessia Cavo, Floriana Morgillo, Andrea Sbrana, Piera Federico, Maria Grazia Vitale, Sandro Pignata, Antonia Silvestri, Paola Taveggia, Sara Merler, Paolo A. Ascierto, Michelino De Laurentiis, Ottaviano, Margaret, Curvietto, Marcello, Rescigno, Pasquale, Tortora, Marianna, Palmieri, Giovannella, Giannarelli, Diana, Aieta, Michele, Assalone, Pasquale, Attademo, Laura, Avallone, Antonio, Bloise, Francesco, Bosso, Davide, Borzillo, Valentina, Buono, Giuseppe, Calderoni, Giuseppe, Caputo, Francesca, Cartenì, Giacomo, Cavallero, Diletta, Cavo, Alessia, Ciardiello, Fortunato, Conca, Raffaele, Conteduca, Vincenza, De Falco, Stefano, De Felice, Marco, De Laurentiis, Michelino, De Placido, Pietro, De Placido, Sabino, De Santo, Irene, De Stefano, Alfonso, Della Corte, Carminia Maria, Di Franco, Rossella, Di Lauro, Vincenzo, Fabbrocini, Antonietta, Federico, Piera, Festino, Lucia, Giordano, Pasqualina, Giuliano, Mario, Gridelli, Cesare, Grimaldi, Antonio Maria, Lia, Michela, Marretta, Antonella Lucia, Massa, Valentina, Mennitto, Alessia, Merler, Sara, Merz, Valeria, Messina, Carlo, Messina, Marco, Milano, Monica, Minisini, Alessandro Marco, Montesarchio, Vincenzo, Morabito, Alessandro, Morgillo, Floriana, Mucci, Brigitta, Nappi, Lucia, Napolitano, Fabiana, Paciolla, Immacolata, Pagliuca, Martina, Palmieri, Giuseppe, Parola, Sara, Pepe, Stefano, Petrillo, Angelica, Piantedosi, Francovito, Piccin, Luisa, Picozzi, Fernanda, Pietroluongo, Erica, Pignata, Sandro, Prati, Veronica, Riccio, Vittorio, Rosanova, Mario, Rossi, Alice, Russo, Anna, Salati, Massimiliano, Santabarbara, Giuseppe, Sbrana, Andrea, Simeone, Ester, Silvestri, Antonia, Spada, Massimiliano, Tarantino, Paolo, Taveggia, Paola, Tomei, Federica, Vincenzo, Tortora, Trapani, Dario, Trojanello, Claudia, Vanella, Vito, Vari, Sabrina, Ventriglia, Jole, Vitale, Maria Grazia, Vitiello, Fabiana, Vivaldi, Caterina, von Arx, Claudia, Zacchi, Francesca, Zampiva, Ilaria, Zivi, Andrea, Daniele, Bruno, Ascierto, Paolo Antonio, Ottaviano, M., Curvietto, M., Rescigno, P., Tortora, M., Palmieri, G., Giannarelli, D., Aieta, M., Assalone, P., Attademo, L., Avallone, A., Bloise, F., Bosso, D., Borzillo, V., Buono, G., Calderoni, G., Caputo, F., Carteni, G., Cavallero, D., Cavo, A., Ciardiello, F., Conca, R., Conteduca, V., De Falco, S., De Felice, M., De Laurentiis, M., De Placido, P., De Placido, S., De Santo, I., De Stefano, A., Della Corte, C. M., Di Franco, R., Di Lauro, V., Fabbrocini, A., Federico, P., Festino, L., Giordano, P., Giuliano, M., Gridelli, C., Grimaldi, A. M., Lia, M., Marretta, A. L., Massa, V., Mennitto, A., Merler, S., Merz, V., Messina, C., Messina, M., Milano, M., Minisini, A. M., Montesarchio, V., Morabito, A., Morgillo, F., Mucci, B., Nappi, L., Napolitano, F., Paciolla, I., Pagliuca, M., Parola, S., Pepe, S., Petrillo, A., Piantedosi, F., Piccin, L., Picozzi, F., Pietroluongo, E., Pignata, S., Prati, V., Riccio, V., Rosanova, M., Rossi, A., Russo, A., Salati, M., Santabarbara, G., Sbrana, A., Simeone, E., Silvestri, A., Spada, M., Tarantino, P., Taveggia, P., Tomei, F., Vincenzo, T., Trapani, D., Trojanello, C., Vanella, V., Vari, S., Ventriglia, J., Vitale, M. G., Vitiello, F., Vivaldi, C., Von Arx, C., Zacchi, F., Zampiva, I., Zivi, A., Daniele, B., and Ascierto, P. A.

Subjects
Male, Cancer Research, Immune checkpoint inhibitors, Programmed Cell Death 1 Receptor, Practice Patterns, Medical Oncology, B7-H1 Antigen, Antineoplastic Agents, Immunological, 0302 clinical medicine, Drug Prescription, Neoplasms, Surveys and Questionnaires, Pandemic, Prevalence, Surveys and Questionnaire, Infection control, Immunology and Allergy, CTLA-4 Antigen, 030212 general & internal medicine, Viral, Practice Patterns, Physicians', RC254-282, Clinical/Translational Cancer Immunotherapy, Oncologists, Geography, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, antineoplastic protocols, Immunological, Oncology, Italy, 030220 oncology & carcinogenesis, Molecular Medicine, Female, immunotherapy, Coronavirus Infections, Human, healthcare economics and organizations, Adult, Telemedicine, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Pneumonia, Viral, Immunology, Antineoplastic Agents, lung neoplasms, Drug Prescriptions, Time-to-Treatment, 03 medical and health sciences, Betacoronavirus, medicine, melanoma, COVID-19, Humans, Infection Control, Pandemics, SARS-CoV-2, Medical prescription, Pharmacology, Physicians', Betacoronaviru, Coronavirus Infection, Cancer, Outbreak, Pneumonia, medicine.disease, lung neoplasm, antineoplastic protocol, Family medicine, healthcare economics and organization, Oncologist, Neoplasm
Abstract

BackgroundThe coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted the practice and adaptations in the management of patients with solid tumors eligible or receiving ICIs during the COVID-19 pandemic, with a special focus on Campania region.MethodsThis survey (25 questions), promoted by the young section of SCITO (Società Campana di ImmunoTerapia Oncologica) Group, was circulated among Italian young oncologists practicing in regions variously affected by the pandemic: high (group 1), medium (group 2) and low (group 3) prevalence of SARS-CoV-2–positive patients. For Campania region, the physician responders were split into those working in cancer centers (CC), university hospitals (UH) and general hospitals (GH). Percentages of agreement, among High (H) versus Medium (M) and versus Low (L) group for Italy and among CC, UH and GH for Campania region, were compared by using Fisher’s exact tests for dichotomous answers and χ2 test for trends relative to the questions with 3 or more options.ResultsThis is the first Italian study to investigate the COVID-19 impact on cancer immunotherapy, unique in its type and very clear in the results. The COVID-19 pandemic seemed not to affect the standard practice in the prescription and delivery of ICIs in Italy. Telemedicine was widely used. There was high consensus to interrupt immunotherapy in SARS-CoV-2–positive patients and to adopt ICIs with longer schedule interval. The majority of the responders tended not to delay the start of ICIs; there were no changes in supportive treatments, but some of the physicians opted for delaying surgeries (if part of patients’ planned treatment approach). The results from responders in Campania did not differ significantly from the national ones.ConclusionOur study highlights the efforts of Italian oncologists to maintain high standards of care for CPs treated with ICIs, regardless the regional prevalence of COVID-19, suggesting the adoption of similar solutions. Research on patients treated with ICIs and experiencing COVID-19 will clarify the safety profile to continue the treatments, thus informing on the most appropriate clinical conducts.

Published
2020

19. Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC.

Author

Mencoboni M, Filiberti RA, Taveggia P, Del Corso L, Del Conte A, Covesnon MG, Puccetti C, Donati S, Auriati L, Amoroso D, and Camerini A

Subjects
Administration, Metronomic, Administration, Oral, Age Factors, Aged, Aged, 80 and over, Antineoplastic Agents, Phytogenic adverse effects, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung pathology, Disease-Free Survival, Feasibility Studies, Female, Humans, Italy, Kaplan-Meier Estimate, Lung Neoplasms mortality, Lung Neoplasms pathology, Male, Medication Adherence, Pilot Projects, Time Factors, Treatment Outcome, Vinblastine administration & dosage, Vinblastine adverse effects, Vinorelbine, Antineoplastic Agents, Phytogenic administration & dosage, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Vinblastine analogs & derivatives
Abstract

Background/aim: The optimal therapeutic use of metronomic vinorelbine has not yet been defined. We aimed to assess the safety of metronomic oral vinorelbine in first-line treatment of elderly patients with advanced lung cancer who were unfit for polychemotherapy. Progression-free survival, response rate and overall survival were secondary end-points., Patients and Methods: Seventy-six patients received 50 mg of oral vinorelbine three times per week, until disease progression, patient refusal or unacceptable toxicity. Patients were evaluated for response and toxicity after one cycle of chemotherapy. The treatment was considered feasible with a grade 3/4 toxicity rate lower than 20%., Results: Clinical benefit was observed in 50% of patients. Median overall survival was 8.0 months. Grade 1/2 toxicity was observed in 53 patients (69.7%), grade 3 toxicity in eight patients (10.5%). One patient had grade 4 diarrhea., Conclusion: Metronomic oral vinorelbine is safe in elderly patients, allowing for long-term disease stabilization with optimal patient compliance., (Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2017
Full Text
View/download PDF

20. Phase II trial of irinotecan and raltitrexed in chemotherapy-naive advanced colorectal cancer.

Author

Chiara S, Nobile MT, Tomasello L, Acquati M, Taveggia P, Murolo C, Percivale P, and Rosso R

Subjects
Aged, Camptothecin adverse effects, Diarrhea chemically induced, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Irinotecan, Male, Middle Aged, Neoplasm Metastasis, Neutropenia chemically induced, Quinazolines adverse effects, Survival Analysis, Thiophenes adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Colorectal Neoplasms drug therapy, Quinazolines administration & dosage, Thiophenes administration & dosage
Abstract

Background: Irinotecan and raltitrexed are active agents in advanced colorectal cancer (ACC) and preclinical data suggest a remarkable synergistic activity. Phase I studies demonstrated that single-agent full dose of both drugs can be administered with moderate toxicity. The aim of this phase II trial was to assess the activity and tolerability of the combination in untreated ACC., Patients and Methods: Forty-eight patients entered the trial and received irinotecan 350 mg/m2 d.1 and raltitrexed 3 mg/m2 d.2, every three weeks. After recruitment of the first 16 patients, grade III-IV toxicity was observed in 6 patients (38%). Therefore, an amendment reduced by 15% the dose of both drugs (irinotecan 300 mg/m2, raltitrexed 2.6 mg/m2)., Results: A total of 290 cycles were administered (range 1-18, median number 6). According to intention-to-treat analysis, the overall response rate was 27% (95% confidence interval 16%-42%), including 3 complete responses and 10 partial responses. The median duration of response was 10 months, while median progression-free survival and overall survival were 5 and 14 months, respectively. In the first 16 patients, the main toxicities were grade III-IV diarrhea in 25% and grade III-IV neutropenia in 13%. In the subsequent 32 patients, they were grade III-IV diarrhea in 34% and grade III neutropenia in 6%. Two toxic deaths occurred., Conclusion: The combination irinotecan-raltitrexed is an active regimen, but the significant incidence of side-effects requires accurate patient selection and, eventually, new schedules.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results